Table 1.
Characteristics of patients from the U.S. and Canada who received and registered an autologous transplant to the CIBMTR, 1994–2005.
| Variable | 1994–1995 N (%) |
1996–1997 N (%) |
1998–1999 N (%) |
2000–2001 N (%) |
2002–2003 N (%) |
2004–2005 N (%) |
|---|---|---|---|---|---|---|
| Patient related | ||||||
| Number of patients | 10,557 | 13,665 | 14,129 | 9686 | 9449 | 10,918 |
| Number of centers | 197 | 225 | 241 | 229 | 210 | 203 |
| Age | ||||||
| Median (range), years | 44 (<1–75) | 46 (<1–76) | 48 (<1–78) | 50 (<1–78) | 52 (<1–91) | 53 (<1–81) |
| < 1–9 | 435 ( 4) | 430 ( 3) | 577 ( 4) | 434 ( 4) | 503 ( 5) | 532 ( 5) |
| 10–19 | 384 ( 4) | 386 ( 3) | 419 ( 3) | 342 ( 4) | 305 ( 3) | 366 ( 3) |
| 20–29 | 819 ( 8) | 849 ( 6) | 838 ( 6) | 708 ( 7) | 599 ( 6) | 680 ( 6) |
| 30–39 | 2129 (20) | 2363 (17) | 2060 (15) | 1121 (12) | 902 (10) | 907 ( 8) |
| 40–49 | 3453 (33) | 4406 (32) | 3945 (28) | 2004 (21) | 1689 (18) | 1824 (17) |
| 50–59 | 2622 (25) | 3845 (28) | 4438 (31) | 2960 (31) | 2869 (30) | 3292 (30) |
| 60–69 | 671 ( 6) | 1317 (10) | 1731 (12) | 1902 (20) | 2203 (23) | 2766 (25) |
| ≥ 70 | 22 (<1) | 54 (<1) | 111 ( 1) | 203 ( 2) | 377 ( 4) | 548 ( 5) |
| Missing | 22 (<1) | 15 (<1) | 10 (<1) | 12 (<1) | 2 (<1) | 3 (<1) |
| Male gender | 3549 (34) | 4352 (32) | 4995 (35) | 5306 (55) | 5382 (57) | 6463 (59) |
| Missing | 58 ( 1) | 11 (<1) | 56 (<1) | 12 (<1) | 26 (<1) | 25 (<1) |
| Karnofsky/Lansky performance score | ||||||
| ≥ 80 | 4012 (38) | 5171 (38) | 4659 (33) | 6426 (66) | 7293 (77) | 8631 (79) |
| < 80 | 231 ( 2) | 302 ( 2) | 291 ( 2) | 427 ( 4) | 479 ( 5) | 617 ( 6) |
| Missing | 6314 (60) | 8192 (60) | 9179 (65) | 2833 (29) | 1677 (18) | 1670 (15) |
| Race | ||||||
| White | 6297 (60) | 8910 (65) | 11,402 (81) | 7731 (80) | 7455 (79) | 8653 (79) |
| African-American | 458 (4) | 661 ( 5) | 1056 (7) | 830 (9) | 912 (10) | 1063 (10) |
| Asian/Pacific Islander | 110 (1) | 159 ( 1) | 225 (2) | 181 (2) | 150 ( 2) | 186 ( 2) |
| Hispanic | 259 (2) | 332 ( 2) | 538 (4) | 330 (3) | 281 ( 3) | 228 ( 2) |
| Other | 34 (<1) | 46 (<1) | 80 (1) | 116 (1) | 158 ( 2) | 426 ( 4) |
| Missing | 3399 (32) | 3557 (26) | 828 (6) | 498 (5) | 493 ( 5) | 362 ( 3) |
| Country | ||||||
| US | 9820 (93) | 12674 (93) | 12998 (92) | 8560 (88) | 8323 (88) | 9717 (89) |
| Canada | 737 (7) | 991 ( 7) | 1131 (8) | 1126 (12) | 1126 (12) | 1201 (11) |
| Disease related | ||||||
| Disease | ||||||
| Multiple myeloma | 678 (6) | 1360 (10) | 2317 (16) | 3091 (32) | 3858 (41) | 4773 (44) |
| Non-Hodgkin lymphoma | 2573 (24) | 3060 (22) | 3079 (22) | 3140 (32) | 2842 (30) | 3164 (29) |
| Hodgkin lymphoma | 906 (9) | 1007 ( 7) | 1158 (8) | 1098 (11) | 1135 (12) | 1302 (12) |
| Solid tumor (not breast cancer) | 968 (9) | 1263 ( 9) | 1445 (10) | 883 (9) | 892 ( 9) | 963 ( 9) |
| Acute myeloid leukemia (AML) | 639 (6) | 499 ( 4) | 575 (4) | 442 (5) | 472 ( 5) | 506 ( 5) |
| Breast cancer | 4401 (42) | 6148 (45) | 5199 (37) | 815 (8) | 125 ( 1) | 61 ( 1) |
| Acute lymphoblastic leukemia (ALL) | 133 (1) | 79 ( 1) | 75 (1) | 40 (<1) | 27 (<1) | 43 (<1) |
| Chronic lymphocytic leukemia (CLL) | 28 (<1) | 47 (<1) | 80 (1) | 61 (1) | 27 (<1) | 24 (<1) |
| Autoimmune diseases | 0 | 12 (<1) | 36 (<1) | 49 (1) | 28 (<1) | 22 (<1) |
| Myelodysplastic syndrome/Myeloproliferative disorder (MDS/MPS) | 22 (<1) | 22 (<1) | 33 (<1) | 24 (<1) | 16 (<1) | 13 (<1) |
| Other leukemia | 63 (1) | 52 (<1) | 27 (<1) | 15 (<1) | 12 (<1) | 11 (<1) |
| Chronic myeloid leukemia (CML) | 88 (1) | 67 (<1) | 80 (1) | 17 (<1) | 4 (<1) | 5 (<1) |
| Other | 42 (<1) | 32 (<1) | 18 (<1) | 9 (<1) | 11 (11) | 31 (<1) |
| Missing | 16 (<1) | 17 (<1) | 7 (<1) | 2 (<1) | 0 | 0 |
| Disease status pre-transplant | ||||||
| AML | ||||||
| 1st complete remission (CR) | 336 (53) | 262 (53) | 313 (54) | 276 (62) | 329 (70) | 338 (67) |
| 2nd or greater CR | 148 (23) | 108 (22) | 139 (24) | 95 (21) | 100 (21) | 126 (25) |
| Relapse/Primary induction failure | 91 (14) | 63 (13) | 68 (12) | 31 ( 7) | 23 ( 5) | 22 ( 4) |
| Other/Unknown/Missing | 64 (10) | 66 (13) | 55 (10) | 40 ( 9) | 20 ( 4) | 20 ( 4) |
| ALL | ||||||
| 1st CR | 46 (35) | 30 (38) | 29 (39) | 23 (58) | 18 (67) | 28 (65) |
| 2nd or greater CR | 63 (47) | 28 (35) | 23 (31) | 10 (25) | 7 (26) | 10 (23) |
| Relapse/Primary induction failure | 17 (13) | 12 (15) | 14 (19) | 6 (15) | 1 ( 4) | 1 ( 3) |
| Other/Unknown/Missing | 7 ( 5) | 9 (11) | 9 (12) | 1 ( 3) | 1 ( 4) | 4 ( 9) |
| Non-Hodgkin lymphoma | ||||||
| 2nd CR /1st chemosensitive relapse | 895 (35) | 1073 (35) | 1050 (34) | 1026 (33) | 952 (34) | 1118 (35) |
| 1st CR | 238 ( 9) | 241 ( 8) | 363 (12) | 409 (13) | 509 (18) | 636 (20) |
| ≥3rd CR / ≥2nd chemosensitive relapse | 211 ( 8) | 252 ( 8) | 304 (10) | 274 ( 9) | 226 ( 8) | 259 ( 8) |
| Other/Unknown/Missing | 1229 (48) | 1494 (49) | 1362 (44) | 1431 (46) | 1155 (41) | 1151 (36) |
| Hodgkin lymphoma | ||||||
| 2nd CR /1st chemosensitive relapse | 348 (38) | 387 (38) | 468 (41) | 440 (40) | 477 (42) | 578 (44) |
| 1st CR | 21 ( 2) | 21 ( 2) | 47 ( 4) | 50 ( 5) | 47 ( 4) | 81 ( 6) |
| ≥3rd CR / ≥2nd chemosensitive relapse | 106 (12) | 88 ( 9) | 113 (10) | 94 ( 9) | 70 ( 6) | 100 ( 8) |
| Other/Unknown/Missing | 431 (48) | 511 (51) | 530 (46) | 514 (47) | 541 (48) | 543 (42) |
| Multiple Myeloma | ||||||
| 1st complete or partial remission | 153 (23) | 366 (27) | 667 (29) | 1554 (50) | 2407 (62) | 3196 (67) |
| Othera | 342 (50) | 499 (37) | 648 (28) | 802 (26) | 907 (24) | 1009 (21) |
| Unknown/Missing | 183 (27) | 495 (36) | 1002 (43) | 735 (24) | 544 (14) | 568 (12) |
| Transplant related | ||||||
| Time from diagnosis to transplant | ||||||
| Median (range) | 14 (<1–563) | 12 (<1–619) | 11 (<1–850) | 11 (<1–734) | 10 (<1–411) | 10 (<1–877) |
| < 12 months | 4472 (42) | 6414 (47) | 7049 (50) | 4899 (51) | 5133 (54) | 6035 (55) |
| 12–23 months | 2068 (20) | 2391 (17) | 2566 (18) | 2024 (21) | 1886 (20) | 2271 (21) |
| 24–35 months | 1105 (10) | 1325 (10) | 1262 (9) | 891 (9) | 731 (8) | 883 (8) |
| ≥ 36 months | 2351 (22) | 2842 (21) | 2658 (19) | 1497 (15) | 1379 (15) | 1656 (15) |
| Missing | 561 ( 5) | 693 ( 5) | 594 (4) | 375 (4) | 320 (3) | 73 (1) |
| Graft sourceb | ||||||
| Peripheral blood | 6288 (60) | 11253 (82) | 12961 (92) | 9104 (94) | 9104 (96) | 10618 (97) |
| Bone marrow | 2730 (26) | 1470 (11) | 657 (5) | 296 (3) | 193 (2) | 208 (2) |
| Bone marrow and peripheral blood | 1539 (15) | 942 ( 7) | 509 (4) | 286 (3) | 151 (2) | 92 (1) |
| High dose therapy regimens | ||||||
| Melphalan | 205 (2) | 486 (4) | 1089 (8) | 1989 (21) | 2833 (30) | 3828 (35) |
| BEAM | 73 (1) | 141 (1) | 537 (4) | 805 (8) | 1066 (11) | 1222 (11) |
| Cy+Etoposide+Nitrosourea | 1219 (12) | 1469 (11) | 1474 (10) | 1100 (11) | 826 (9) | 944 (9) |
| Bu+Cy ± other | 1173 (11) | 1162 (9) | 1128 (8) | 938 (10) | 800 (8) | 730 (7) |
| Cy ± other | 2471 (23) | 2900 (21) | 2356 (17) | 847 (9) | 485 (5) | 404 (4) |
| Cy+TBI ± other | 1135 (11) | 1021 (7) | 1015 (7) | 647 (7) | 370 (4) | 321 (3) |
| Etoposide + Melphalan ± other | 165 (2) | 142 (1) | 154 (1) | 99 (1) | 116 (1) | 260 (2) |
| BEAM+MAB ± other | 0 | 0 | 14 (<1) | 43 (<1) | 100 (1) | 200 (2) |
| Bu+Etoposide ± other | 67 (1) | 69 (1) | 142 (1) | 94 (1) | 137 (1) | 147 (1) |
| Carboplatin + Etoposide + Melphalan ± other | 104 (1) | 166 (1) | 240 (2) | 95 (1) | 204 (2) | 134 (1) |
| Carboplatin + Thiotepa ± other | 146 (1) | 147 (1) | 146 (1) | 116 (1) | 147 (2) | 94 ( 1) |
| Melphalan ± other (no radiation) | 34 (<1) | 41 (<1) | 193 (1) | 151 (2) | 102 (1) | 89 ( 1) |
| Carboplatin + Etoposide | 66 (1) | 97 (1) | 58 (<1) | 53 (1) | 69 (1) | 88 ( 1) |
| TBI ± other | 234 (2) | 540 (4) | 732 (5) | 357 (4) | 78 (1) | 78 ( 1) |
| Bu+ Melphalan ± other (no Thio) | 36 (<1) | 65 (<1) | 46 (<1) | 34 (<1) | 42 (<1) | 72 ( 1) |
| Bu+ Melphalan +Thiotepa ± other | 41 (<1) | 165 (1) | 141 (1) | 58 (1) | 28 (<1) | 70 ( 1) |
| Cy+Thiotepa+Carboplatin | 1625 (15) | 2793 (20) | 2854 (20) | 380 (4) | 33 (<1) | 21 (<1) |
| Carboplatin + Etoposide + Ifosfamide ± other | 164 (2) | 109 (1) | 77 (1) | 27 (<1) | 18 (<1) | 5 (<1) |
| Other | 1304 (12) | 1374 (10) | 1120 (8) | 457 (5) | 374 (4) | 399 ( 4) |
| Missing | 295 (3) | 778 (6) | 613 (4) | 1396 (14) | 1621 (17) | 1812 (17) |
| Type of 2nd transplant | ||||||
| 1 transplant only | 9741 (92) | 12609 (92) | 12980 (92) | 8636 (89) | 8230 (87) | 9151 (84) |
| 2 or more transplants | ||||||
| 1st autologous-2nd allogeneic, 2nd planned | 1 (<1) | 4 (<1) | 7 (<1) | 24 (<1) | 61 (1) | 145 (1) |
| 1st autologous-2nd allogeneic, 2nd not planned | 193 (2) | 282 (2) | 380 (3) | 429 (4) | 505 (5) | 485 (4) |
| 1st autologous-2nd autologous, 2nd planned | 167 (2) | 289 (2) | 313 (2) | 277 (3) | 285 (3) | 786 (7) |
| 1st autologous-2nd autologous, 2nd not planned | 455 (4) | 479 (4) | 447 (3) | 317 (3) | 364 (4) | 345 (3) |
| Missing | 0 | 2 (<1) | 2 (<1) | 3 (<1) | 4 (<1) | 6 (<1) |
Abbreviations: Cy=Cyclophosphamide; TBI=Total Body Irradiation; Bu=Busulfan; BEAM=Nitrosourea+Etoposide+ARAC+Melphalan; MAB=Monoclonal antibody.
a
Others include: Minimal Response, No Response/Stable Disease, Progression/Relapse, 2nd or greater Complete Remission
b
There was one autologous cord blood transplant between 2002–2003 in a 1 year old with severe aplastic anemia.